Back to top

Analyst Blog

The FDA has granted priority review status to AbbVie’s (ABBV - Analyst Report) experimental all-oral, interferon-free therapy for the treatment of adults with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

With the new drug application (NDA) being submitted on Apr 21, AbbVie should receive a response from the FDA early in the fourth quarter.

The experimental HCV regimen has Breakthrough Therapy status which was granted by the FDA in May 2013. Breakthrough Therapy status, a new designation that became effective after Jul 9, 2012, is designed to cut short the development time of promising new treatments.

The HCV regimen has also been submitted for review in the EU where the marketing application was filed in May.

AbbVie’s HCV regimen comprises ABT-450/ritonavir co-formulated with ombitasvir (ABT-267), and dasabuvir (ABT-333) with or without ribavarin. AbbVie has presented impressive data on the experimental regimen and the NDA includes data from six phase III studies. First-round approval could very well result in this new treatment hitting the market by year end.

The HCV market is attracting a lot of interest - Gilead’s (GILD - Analyst Report) Sovaldi has been bringing in billions of dollars within a few months of its approval despite concerns regarding its high price. Plus there is space in the market for additional treatments. Interest in the HCV market increased further with pharma giant Merck (MRK - Analyst Report) recently announcing its intention to acquire HCV focused Idenix Pharmaceuticals, Inc. for about $3.85 billion.

Several companies are looking to bring the next generation of HCV treatments to market. Gilead itself is looking to get its once-daily fixed-dose HCV cocktail treatment -- ledipasvir (NS5A inhibitor) plus Sovaldi (nucleotide analog polymerase inhibitor) -- approved in the U.S.

AbbVie is a Zacks Rank #3 (Hold) stock. Gilead, which carries a Zacks Rank #1 (Strong Buy), is a better-ranked stock.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%